Clinical trials consume the latter half of the 10 to 15 year, 1.5-2.0 billion USD, development cycle for bringing a single new drug to market. Hence, a failed trial sinks not only the investment into the trial itself but also the preclinical developm...
Stakeholders across the entire healthcare chain are looking to incorporate artificial intelligence (AI) into their decision-making process. From early-stage drug discovery to clinical decision support systems, we have seen examples of how AI can impr...
Several machine learning approaches have been proposed for predicting new benefits of the existing drugs. Although these methods have introduced new usage(s) of some medications, efficient methods can lead to more accurate predictions. To this end, w...
PURPOSE: The Tufts Center for the Study of Drug Development (CSDD) and the Drug Information Association (DIA) in collaboration with 8 pharmaceutical and biotechnology companies conducted a study examining the adoption and effect of artificial intelli...
A variety of machine learning methods such as naive Bayesian, support vector machines and more recently deep neural networks are demonstrating their utility for drug discovery and development. These leverage the generally bigger datasets created from...
The identification of drug-target interactions has great significance for pharmaceutical scientific research. Since traditional experimental methods identifying drug-target interactions is costly and time-consuming, the use of machine learning method...
IEEE reviews in biomedical engineering
Aug 7, 2018
With the recent advancements in analyzing high-volume, complex, and unstructured data, modern learning methods are playing an increasingly critical role in the field of personalized medicine. Personalized medicine (i.e., providing tailored medical tr...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.